Annual report [Section 13 and 15(d), not S-K Item 405]

Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.25.1
Nature of Business and Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Dec. 31, 2024
USD ($)
Segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Aug. 12, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
State of incorporation DE      
Date of incorporation Aug. 03, 2018      
Common stock, conversion description minority stockholder of THIO received one share of MAIA Common Stock for each share of THIO Common Stock owned prior to the merger.      
Common stock, conversion ratio 1      
Working capital $ 6,322,441      
Accumulated deficit (87,234,833) $ (63,980,177)    
Cash $ 9,601,298 7,150,695    
Number of operating segment | Segment 1      
Current liabilities $ 3,830,038 4,937,153    
Revenues 0      
Current cash reserves 9,601,298 7,150,695 $ 10,950,927  
Cash equivalents 0 0    
Deferred offering costs $ 0 0    
Accounting Standards Update [Extensible Enumeration] us-gaap:AccountingStandardsUpdate201602Member      
Warrant liability $ 2,690,605 $ 2,152,188    
Cash deposits federally insured limits $ 250,000      
ASU 2023-07        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Change in Accounting Principle, Accounting Standards Update, Adopted [true false] true      
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] true      
MAIA Biotechnology, Inc. | THIO Therapeutics, Inc.        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Ownership percentage by parent       93.30%
Minority stockholder ownership percentage       6.70%